Category Archives: Molecular Medicine

Tributes are pouring in at news of the death of John Bienenstock, known internationally as a visionary physician, scientist, academic and a leader at McMaster University. He died July 25 at age 85.

The professor of pathology officially retired in 1998, but he remained active in his research and as director of the McMaster Brain Body Institute at St. Josephs Healthcare Hamilton until his death.

During his tenure at McMaster, he became renowned worldwide as a pioneer in mucosal immunology introducing the concept of a common mucosal immune system. He also advanced the knowledge of neuroimmunology and in understanding how the brain and nervous system collaborate. He published more than 500 peer-reviewed articles and authored, edited or co-edited 10 books including a standard textbook on mucosal immunology and allergy.

He was chair of the Department of Pathology from 1978 to 1989, and dean and vice-president of the Faculty of Health Sciences at McMaster from 1989 to 1997. He was known for establishing a substantial research infrastructure at the Faculty.

His accomplishments were recognized. He became a Fellow of the Royal Society of Canada in 1992; a McMaster Distinguished University Professor in 1999; a member of the Order of Canada in 2002 and was inducted into the Canadian Medical Hall of Fame in 2011. He became a member of the Faculty of Health Sciences Community of Distinction in 2014. He also received an honorary MD from Goteborg, Sweden.

He was born in Budapest, Hungary in 1936, obtained his medical degree at Kings College London and Westminster Hospital Medical School, U.K. in 1960, and did a postdoctoral term at Harvard University before joining McMaster Universitys medical school start-up in 1968. The first class began in 1969.

Bienenstock was also a mentor and friend to many graduate students and fellow researchers, supervising more than 60 post doctoral fellows and 10 doctoral students.

He leaves his family: his wife Dody; their children, the late Jimson (Johanna), Adam (Jill), and Robin; their grandchildren, Bella, Elsa, Sam, Leo, Sebastiano and Oliva and his sister Tsultrim Zangmo (Veronica).

Typical of the tributes, is this one from Dr. Kevin Smith, former CEO of St. Josephs Healthcare and current President & CEO, University Health Network John was the single most important mentor in my career and unquestionably the most creative person a true renaissance man I have ever had the privilege of working with. He took great joy in the success of others and made hard work fun. He became a dear and beloved friend who I will forever treasure and miss.

Dr. John Bienenstock has had an immense impact on the Faculty since he started here 54 years ago. He was a visionary as a scientist, as an administrator and as an academic, inspiring generations of scientists and clinicians to think outside of the box. He was a friend and mentor to so many of us, and his legacy of innovation will continue, Paul OByrne, Distinguished University Professor, Medicine, and Dean and Vice-President, Faculty of Health Sciences, McMaster University.

John Bienenstock was a remarkably creative individual, a revolutionary thinker and a pioneer in the study of mucosal Immunology. Johns impact on our community has been deep and far-reaching. As holder of the John Bienenstock Chair in Molecular Medicine, I am continually inspired by Johns legacy of scientific excellence and impact, Jonathan Bramson, Professor, Medicine and Vice-Dean, Research, Faculty of Health Sciences, McMaster University

The Canadian Medical Hall of Fames 2011 tribute to John Bienenstock is here. https://www.youtube.com/watch?v=yyXxiBw8qlQ

Get notified about exclusive offers every week!

Go here to see the original:
Distinguished health researcher, hospital executive John Bienenstock remembered - The Bay Observer - Providing a Fresh Perspective for Hamilton and...

The arms race between the human immune system and gonorrhea might have had the useful side effect of promoting healthy brain tissue later in life.

This tiny boost to cognitive health in our twilight years might have played a small role in ensuring grandmas were sharp-minded enough for evolution to keep them around.

While its fiendishly difficult and may be impossible to figure out what evolutionary factors are responsible for living beyond ages where we no longer reproduce, researchers at the University of California, San Diego, are closing in on some possible explanations.

In2015, a team of researchers led by molecular medicine professor Ajit Varki discovered that humans have a unique type of immune receptor that protects againstAlzheimersdisease and sets us apart from other primates.

In apaperpublished this month, the team found that the spreading of this variant immune receptor in our species wasnt entirely random, but rather the result of intense selection pressure over a relatively brief period.

The research showed that some of our closest relatives NeanderthalsandDenisovans did not have this version of immune receptors coded into their genomes. Something drove humans to develop this special immune receptor early in our history as a species, the researchers said.

The likely culprits are infectious human-specific pathogens likeNeisseria gonorrhoeae that try to disguise themselves by dressing in the same sugar coating as human cells, which fools patrolling immune cells into thinking the bacteria are harmless.

The researchers showed that the newly evolved immune receptor could see through the disguise and kill the invading bacteria, while the older variation of the immune receptor could not.

Getting rid of gonorrhea is useful for the survival of the species because this disease can mess with human reproduction.

The new version of the immune receptor is called huCD33. Thanks to the way this version is tweaked into two subtly different structures within our body, its been the subject of investigations by evolutionary scientists for some time.

Once evolved, this immune receptor was probably co-oped by brain immune cells, called microglia, for a different purpose: protection against aging, the researchers suggest.

The human immune system usually doesnt attack itself on purpose, but it needs to when cells start to decay.

The huCD33 receptor, which seems to have evolved as a response to sneaky bacteria, had the added benefit of being able to recognize decaying brain tissue and thereby protect cognitive function in old age.

Microglia use the huCD33 receptor to clear away damaged brain cells and amyloid plaques associated with Alzheimers disease.Whether this might have played a role in clearing the way for evolution to add a few more precious years to our lives for the sake of helping out with raising families is a topic open to debate.

Grandparents provide benefits to the human species as they help to look after kids and pass on important cultural knowledge. And gonorrhea may be to thank for that.

Read the original post here

Continue reading here:
Did the prevalence of gonorrhea in early humans lead to long-living and protective grandmothers? - Genetic Literacy Project

Eunice Yuen, MD, PhD, assistant professor of psychiatry, has been selected to participate in the 2022-23 Women Faculty Forum Public Voices Fellowship at Yale.

The program gives under-represented minority scholars the opportunity to work with top journalists from The OpEd Project. Fellows receive support in all areas of public thought leadership, including writing and placing op-ed pieces, conducting TV and radio interviews, and using social media.

The fellowship is designed to assist scholars in increasing their influence as thought leaders whose ideas impact not only academia but also larger public debates.

The OpEd Project works with universities and other organizations to train under-represented experts to take thought leadership positions in their fields through op-eds and other means.

Before joining the Yale School of Medicine faculty, Yuen completed the Albert J. Solnit Integrated Training Program in Adult, Child and Adolescent Psychiatry and Research at the Yale Department of Psychiatry and Yale Child Study Center. Her neuroscience PhD research focused on cellular and molecular mechanisms of emotional stress in the brain and how emotional stress affects mental health.

Yuen is also founder and director of Yale Compassionate Home, Action Together (CHATogether), a culturally- and family-oriented program using drama vignettes as educational tools to promote emotional wellness in Asian-American children, young adults, and parents.

Submitted by Christopher Gardner on August 03, 2022

More here:
Yuen Selected to Participate in WFF Public Voices Fellowship - Yale School of Medicine

Welcome to OncLive On Air! Im your host today, Caroline Seymour.

OncLive On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In todays episode, we spoke with William J. Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology, chief of Hematology and Oncology, and a professor of hematology and oncology in the Department of Medicine at the Feinberg School of Medicine at Northwestern University.

In our exclusive interview, Dr Gradishar emphasized the importance of defining metastatic breast cancer subtypes and discussed the implications of molecular testing and genetics on treatment decisions. He also explained the process of determining disease subtypes as breast cancer cases shift from early-stage to metastatic, and highlighted the need for honest and comprehensive patient-provider communication about therapeutic options and clinical trial opportunities throughout the course of disease.

___

Thats all we have for today! Thank you for listening to this episode of OncLive On Air. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit http://www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked todays episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Here is the original post:
Gradishar Stresses the Importance of Accurately Defining Breast Cancer Subtypes - OncLive

HELSINKI, Aug. 2, 2022 /PRNewswire/ --Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced four appointments to its Scientific Advisory Board (SAB), Professor Paolo A. Ascierto, Dr Jeffery Bockman, Professor Malcolm K. Brenner, and Professor Kevin Harrington.

ValoTx's CEO, Paul Higham, said, "We are delighted to welcome our distinguished, and expert, new SAB members. They bring a wealth of scientific and clinical understanding which will be of great help in progressing our antigen-coated oncolytic viruses and vaccine vectors as innovative immunotherapy approaches against cancer and infectious diseases. We look forward to working with them all."

ValoTx's Scientific Advisory Board chair, Professor Vincenzo Cerullo, said, "It's a great pleasure to have such top international scientific and clinical talent join me on Valo's Scientific Advisory Board. Our innovative solutions to vaccines, immuno-oncology and personalised cancer treatments are life-changing and will overcome some of medicine's greatest challenges."

Professor Paolo Antonio Ascierto is a world-leading key opinion leader in melanoma disease and immunotherapy. He is currently Director of the Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Cancer Institute "Pascale" in Naples, Italy. He is Editorial Board Member, Editor and Scientific Reviewer for leading medical journals and a member of the Steering Committee of the Society of Melanoma Research (SMR). Dr Ascierto is part of the Board of Directors for the Society of ImmunoTherapy of Cancer (SITC) and of the Cancer Development Drug Forum (CDDF), and is President of the Fondazione Melanoma Onlus, and the Campania Society of ImmunoTherapy of Cancer (SCITO). He has been an invited speaker to over 400 national and international scientific meetings, courses, and workshops. He has presided as Principle Investigator on over 150 clinical trials, and he is the author of over 600 publications in peer-reviewed journals. His awards and honours are numerous and include receiving the GEF Health Award in 2022. He has received funding from the POR FESR and ERA-NET, among others.

Dr Jeffrey Bockman received a BA from the University of California at San Diego, an MA in English/Creative Writing from New York University, and a PhD in Medical Microbiology from the University of California at Berkeley. He is the Executive Vice President, Head of Oncology at Lumanity BioConsulting, and was an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients: Dr Sidney Altman, on ribozymes, and Dr Stanley Prusiner, on prions. He brings to the SAB extensive commercial and strategic perspective on the pharmaceutical and biotech industries, including leading the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories. He is a frequent speaker at industry events such as BIO on the intersection of scientific, clinical, and strategic issues affecting biotech oncology drug development. Jeff is a member of AACR, ASCO, ASH, ASGCT, SITC and NYAS. He is a mentor for the NCI Innovation Conference, a judge for the Citeline Awards, a member of the Advisory Group to Skipper Bio Med, and is on the Clinical Advisory Board of ImmunOS (Zurich) and the Scientific Advisory Board of hC Bioscience (Cambridge, MA).

ProfessorMalcolm K. Brenner is an award-winning physician-scientist who has pioneered the therapeutic use in cancer of T cell immunologic approaches and genetic engineering strategies. He is the Founding Director, Centre for Cell and Gene Therapy, Baylor College of Medicine (BCM), Houston Methodist Hospital and Texas Children's Hospital. He served as Editor-in-Chief of Molecular Therapy and as former President of the American Society for Gene and Cell Therapy and of the International Society for Cell Therapy. Dr Brenner obtained his medical degrees and PhD from the University of Cambridge, England. Dr Brenner's work has been funded by the NIH-NCI, the Leukemia and Lymphoma Society, the Cancer Prevention and Research Institute of Texas, and several charitable foundations. He has been involved in the foundation of several companies, such as Allovir, Marker Therapeutics, and Tessa Therapeutics.

Professor Kevin Harrington qualified in medicine from the University of London and obtained his PhD from Imperial College, London. He is a Fellow of the Royal College of Physicians and the Royal College of Radiologists. He completed postgraduate training in clinical oncology (Royal College of Radiologists Rohan Williams medallist) and postdoctoral research in Professor Richard Vile's laboratory at the Molecular Medicine Programme in the Mayo Clinic. He subsequently was appointed to a group leader position at The Institute of Cancer Research (ICR), London and an honorary consultant oncologist post at the Royal Marsden Hospital (RMH). He is the Head of the Division of Radiotherapy and Imaging at the ICR, and Director of the CRUK ICR/RMH RadNet Centre of Excellence. He has led phase I, II and III trials of oncolytic virotherapies, immunotherapy and radiation-drug combinations. He brings to the SAB a longstanding focus on gene therapy and viral gene therapy as ways to selectively destroy cancer cells and activate anti-tumour immune responses. His laboratory research focuses on the use of biologically targeted agents, in combination with treatments such as radiotherapy and chemotherapy, to target cancer cells selectively, especially in head and neck cancer and in melanoma.

About ValoTx

Valo Therapeutics Oy (Helsinki) is an immunotherapy company that is developing innovative immunotherapy approaches against cancer and infectious disease. The ValoTx lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenoviruses into targeted tissue specific cancer vaccines without the need to generate and manufacture multiple genetically modified viruses. The company is also developing PeptiENV and PeptiVAX, among other neoantigen strategies, in collaboration with Professor Cerullo. PeptiENV is expected to improve the therapeutic response to oncolytic enveloped viruses in the treatment of multiple forms of cancer, while PeptiVAX is a program to develop a novel, adaptable anti-infectives vaccination platform. The lead PeptiVAX project is a T-cell pan-Coronavirus vaccine. The company's PeptiCHIP technology enables the rapid and accurate identification of tumor antigens. A film explaining the PeptiCRAd technology can be found here.

SOURCE Valo Therapeutics

Read more here:
Valo Therapeutics Announces Scientific Advisory Board - PR Newswire

image:Professor Tuuli Lappalainen, Associate Member of the New York Genome Center and one of the leaders of the study. view more

Credit: NYGC

NEW YORK, NY (August 3, 2022) Research on RNA diversity in human tissues, led by scientists from the New York Genome Center and the Broad Institute, is described in a recent study published in Nature. When the genetic code is transcribed to RNA, one gene typically produces several different forms of RNA molecules, or transcripts, with different functions. While this phenomenon has been known for decades, the catalog of human transcripts has remained incomplete.Equipped with the latest sequencing technology, we were able to read segments of over one thousand nucleotides, compared to less than one hundred with standard approaches, describes Dr. Beryl Cummings, one of the leaders of the project and formerly a postdoctoral fellow at the Broad Institute. Importantly, we were able to do this at scale of over 80 samples from many tissues, which led to discovery of tens of thousands of novel transcripts, she adds.The researchers used their data to characterize how genetic and environmental differences can manifest in differences in the transcriptome. Genetic differences between individuals can affect how genes are regulated. We were able to describe with a finer resolution than before how transcript structures are affected. This helps to understand molecular underpinnings of variants that contribute to disease risk, explains Dr. Dafni Glinos from the New York Genome Center and co-first author of the study.

We believe the discoveries, data, and tools we present pave the way for a new era of transcriptome research. About a decade ago, high-through analysis of small DNA or RNA segments revolutionized genomics. I think were at the cusp of a new revolution with long read sequencing says Professor Tuuli Lappalainenfrom the New York Genome Center andone of the leaders of the study.

# # #

About the New York Genome Center

The New York Genome Center (NYGC)is an independent, nonprofit academic research institution that serves as a multi-institutional hub for collaborative genomic research. Leveraging our strengths in technology development, computational biology, and whole-genome sequencing and analysis, our mission is to advance genomic science, and its application to novel biomedical discoveries. NYGCs areas of focus include the development of computational and experimental genomic methods and disease-focused research to advance the understanding of the genetic basis of cancer, neurodegenerative disease, and neuropsychiatric disease. Since 2020, the NYGC has worked with its hospital and academic partners to advance COVID-19 research, whole genome sequencing over 12,000 viral samples to discover new viral variants and explore the genetic basis of severe disease.

Institutional founding members are: Cold Spring Harbor Laboratory, Columbia University, Albert Einstein College of Medicine, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, New York-Presbyterian Hospital, New York University, Northwell Health, The Rockefeller University, Stony Brook University, and Weill Cornell Medicine. Institutional associate members are: American Museum of Natural History, Hospital for Special Surgery, Georgetown Lombardi Comprehensive Cancer Center, Hackensack Meridian Health, The New York Stem Cell Foundation, Princeton University, Roswell Park Cancer Institute and Rutgers Cancer Institute of New Jersey. For more information on the NYGC, please visit:http://www.nygenome.org

Media Contact:

Madisen Grimaldi, NYGC, Senior Communications Associate

mgrimaldi@nygenome.org

c: (215) 870-1149

Scientist Contacts:

Scientist Contact:

Prof. Tuuli Lappalainen Dr. Dafni Glinos Dr. Beryl Cummings

tlappalainen@nygenome.org dafni.glinos@gmail.com berylbcummings@gmail.com

+1-9177532661 or +46-721940550 +44-7564001951 +19197256320

Imaging analysis

Human tissue samples

3-Aug-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Originally posted here:
RNA diversity in human tissues mapped with emerging sequencing technology - EurekAlert

CHICAGO, July 24, 2022 /PRNewswire/ -- At the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo, laboratory medicine experts will present the cutting-edge research and technology that is revolutionizing clinical testing and patient care. From July 24-28 in Chicago, the meeting's 250-plus sessions will deliver insights on a broad range of timely healthcare topics. Highlights include discussions exploring the use of artificial intelligence (AI) in personalized medicine, advances in multiplexed genomic sequencing and imaging, real-life applications of human brain organogenesis, how to build trust with patients, and guiding clinical decisions with mass spectrometry.

(PRNewsfoto/AACC)

AI in Personalized Medicine. Precision medicine involves tailoring treatments to individual patients and, increasingly, clinicians are using AI in their clinical prediction models to do this. In the meeting's opening keynote, Dr. Lucila Ohno-Machado, health associate dean of informatics and technology at the University of California San Diego, will introduce how AI models are developed, tested, and validated as well as performance measures that may help clinicians select these models for routine use.

Multiplexed Genomic Sequencing and Imaging. Thanks to advances in multiplexed genomic sequencing and imaging, we can identify small but crucial differences in DNA, RNA, proteins, and more. These techniques have also undergone a 50-million-fold reduction in cost and comparable improvements in quality since they first emerged. In spite of this, healthcare is just beginning to catch up with the implications of these technologies. Dr. George Church, AACC's 2022 Wallace H. Coulter Lectureship Awardee and founding core faculty and lead at the Synthetic Biology Wyss Institute at Harvard University, will discuss advances and implications of multiplex technologies at this plenary session.

Applications of Human Brain Organoid Technology. The human brain is a very complex biological system and is susceptible to several neurological and neurodegenerative disorders that affect millions of people worldwide. In this plenary session, Dr. Alysson R. Muotri, professor of cellular and molecular medicine at the University of California San Diego School of Medicine, will explore the concept of human brain organogenesis, or how to recreate the human brain in a dish. Several applications of this technology in neurological care will be discussed.

Story continues

Building Trust in Healthcare. The world is having a trust crisis that is affecting healthcare delivery across the globe. Dr. Thomas Lee, chief medical officer of Press Ganey Associates and professor of health policy and management at the Harvard T.H. Chan School of Public Health, will describe the importance of building trust among patients and healthcare workers in this plenary session. He will explore a three-component model for building trust, and the types of interventions most likely to be effective.

Guiding Clinical Decisions with Mass Spectrometry. In this, the meeting's closing keynote, Dr. Livia Schiavinato Eberlin, associate professor of surgery and director of translational and innovations research at Baylor College of Medicine, will discuss the development and application of direct mass spectrometry techniques used in clinical microbiology labs, clinical pathology labs, and the operating room. The presentation will focus on results obtained in ongoing clinical studies employing two direct mass spectrometry techniques, desorption electrospray ionization mass spectrometry imaging and the MasSpec Pen technology.

Additionally, at the Clinical Lab Expo, more than 750 exhibitors will display innovative technologies that are just coming to market in every clinical lab discipline.

"Laboratory medicine's capacity to adapt to changing healthcare circumstances and use the field's scientific insights to improve quality of life is unparalleled. This capacity is constantly growing, with cutting-edge diagnostic technologies emerging every day in areas as diverse as mass spectrometry, artificial intelligence, genomic sequencing, and neurology," said AACC CEO Mark J. Golden. "The 2022 AACC Annual Scientific Meeting will shine a light on the pioneers in laboratory medicine who are mobilizing these new advances to enhance patient care."

Session Information

AACC Annual Scientific Meeting registration is free for members of the media. Reporters can register online here: https://www.xpressreg.net/register/aacc0722/media/landing.asp

AI in Personalized Medicine

Session 11001 Biomedical Informatics Strategies to Enhance Individualized Predictive ModelsSunday, July 245-6:30 p.m.U.S. Central Time

Multiplexed Genomic Sequencing and Imaging

Session 12001 Multiplexed and Exponentially Improving TechnologiesMonday, July 258:45 10:15 a.m.U.S. Central Time

Applications of Human Brain Organoid Technology

Session 13001 Applications of Human Brain Organoid TechnologyTuesday, July 268:45 10:15 a.m.U.S. Central Time

Building Trust in Healthcare

Session 14001 Building Trust in a Time of TurmoilWednesday, July 278:45 10:15 a.m.U.S. Central Time

Guiding Clinical Decisions with Mass Spectrometry

Session 15001 Guiding Clinical Decisions with Molecular Information provided by Direct Mass Spectrometry TechnologiesThursday, July 288:45 10:15 a.m.U.S. Central Time

All sessions will take place in Room S100 of the McCormick Place Convention Center in Chicago.

About the 2022 AACC Annual Scientific Meeting & Clinical Lab ExpoThe AACC Annual Scientific Meeting offers 5 days packed with opportunities to learn about exciting science from July 24-28. Plenary sessions will explore artificial intelligence-based clinical prediction models, advances in multiplex technologies, human brain organogenesis, building trust between the public and healthcare experts, and direct mass spectrometry techniques.

At the AACC Clinical Lab Expo, more than 750 exhibitors will fill the show floor of the McCormick Place Convention Center in Chicago with displays of the latest diagnostic technology, including but not limited to COVID-19 testing, artificial intelligence, mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation.

About AACCDedicated to achieving better health through laboratory medicine, AACC brings together more than 70,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit http://www.aacc.org.

Christine DeLongAACCSenior Manager, Communications & PR(p) 202.835.8722cdelong@aacc.org

Molly PolenAACCSenior Director, Communications & PR(p) 202.420.7612(c) 703.598.0472mpolen@aacc.org

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/artificial-intelligence-in-personalized-medicine-genomic-sequencing-advances-human-brain-organogenesis-building-trust-with-patients-guiding-patient-decisions-with-mass-spectrometry-and-much-more-to-be-explored-at-the-2022-aac-301592069.html

SOURCE AACC

Read more here:
Artificial Intelligence in Personalized Medicine, Genomic Sequencing Advances, Human Brain Organogenesis, Building Trust with Patients, Guiding...

Faculty Positions in Life Science and Medicine at

National Tsing Hua University (Taiwan)

Location

Hsinchu, Taiwan

DeadlinePlease check the following link for information.

Position description and other specified information

Required Qualifications:PhD in related fields.

Application:All applicants are required to submit aCurriculum Vitae and othersupporting materials.

About NTHU (Please find more in company)

At National Tsing Hua University (NTHU), we believe that everyone deserves the opportunity to explore and realize their unique potential. In everything we do, NTHU will continue to uphold our core values of inclusivity, equality, and inclusivity in safeguarding academic freedom and shared governance.NTHU is widely recognized as a foremost incubator of future leaders in industry and academia. NTHUs consistent record of excellence is exemplified by the outstanding achievement of our faculty and alumni, among whom are two Nobel laureates in physics, one Nobel laureate in chemistry, and one Wolf Prize winner in mathematics.

Salary

1.Statutory Salary:

The statutory salary for a full-time facultymember includes Base SalaryandAdditional Academic Research Pay.

(Please refer to https://yushan.site.nthu.edu.tw/p/412-1518-17613.php?Lang=en)

2. Non-statutory (Additional) Salary:

(1) Yushan Fellows and Yushan Young Fellows: If approved by the Ministry of Education as a Yushan Scholar or Yushan Young Scholar, theMOE willprovide the subsidyfor the non-statutory (additional) salary:

(Please refer tohttps://yushan.moe.gov.tw/TopTalent/EN/Intro)

(2) Flexible Salary Reward: If not approved by the MOE Yushan Fellow Program, NTHU may provide a Flexible Salary Reward if it conforms to the regulations of the NTHU Newly-Recruited Faculties Flexible Salary Reward.

(Please refer to https://yushan.site.nthu.edu.tw/p/412-1518-18110.php?Lang=en)

(3) Newly appointed foreigner (non-Taiwanese) faculty members are eligible to apply for an extra compensation of 25,000 NTD/month till 2027.

Taiwan is ranked 19th in global purchasing power parity (PPP) indicating high standard of living with stable and low cost of living.

(Please refer to https://en.wikipedia.org/wiki/List_of_countries_by_GDP_(PPP)#cite_note-:0-1)

We also provide

1. Subsidy for NTHU Newly-Recruited Faculty Academic Research (start-up subsidy)

2. Subsidy for Guest House and Accommodation

3. Education of children

About College of Life Science(https://cls.site.nthu.edu.tw/app/index.php?Lang=en)

Established in 1991 as the very first Department of Life Science in Taiwan, the Department of Life Science allows students to explore various areas of life science in an integrated yet diverse program built upon a solid foundation of chemistry, physics, mathematics and biology. In 2022, the College of Life Science was reorganized and is now comprised of the Department of Life Science, the Department of Medical Science, the Interdisciplinary Program of Life Science, the School of Medicine and five Institutes, the Institute of Molecular and Cell Biology, the Institute of Bioinformatics and Structural Biology, the Institute of Molecular Medicine, the Institute of Biotechnology, and Institute of Systems Neuroscience. The Department of Life Science, Medical Science and Interdisciplinary Program offer undergraduateBachelor of Science(B.Sc.) programs in Biology and Medical Science whereas the five Institutes offer graduate programs in a variety of research areas. The School of Medicine offers Doctor of Medicine.

Five educational goals of the College of Life Science (ERIGS):

1. Education: Excellence in education and learning in the fields of life science

2. Research: Innovative research and research training at the highest international level in the fields of life science

3. Internal Mobilization: Supporting the development of students and colleagues

4. Globalization: Widening global worldview and providing international environment for the studies of life science

5. Social Responsibility: Model for sharing common wealth from life science research

We strive to train our young life scientists as prophetic leaders of future generations with a passion for science, and compassion for life and a desire to transform the world.

Chronology

1973 Institute of Molecular Biology (IMB) established

1974 Masters program for IMB established

1984 Ph.D. program for IMB established

1985 Re-organized as Institute of Life Science

1987 Life Science Building I completed

1991 Institute of Biomedicine and Department of Life Science established

1992 College of Life Science established

1995 All institutes merged into Department of Life Science

1997 Institute of Biotechnology established

1998 Institute of Radiation Biology merged with the College

2002 Reorganized into four institutes and Department of Life Science

2004 Brain Research Center established

2008 Interdisciplinary Program of Life Science and Institute of Systems Neuroscience established

2010 Department of Medical Science established

2013 Interdisciplinary Neuroscience Ph.D. Degree Program established

2016 Ph.D. Program in Bioindustrial Technology established

2022 School of Medicine established

2022 Reorganized into five institutes, three departments and one interdisciplinary program

See original here:
Faculty Positions in Life Science and Medicine at National Tsing Hua University (Taiwan) job with National Tsing Hua University | 37287332 - The...

Singapore-based diagnostics developer INEX Innovate brings The Chinese University of Hong Kong together to further research work on LEXI, INEX's fetal cell based non-invasive pre-natal diagnostics technology.

SINGAPORE, July 26, 2022 /PRNewswire/ -- Singapore-based diagnostics developer and medical laboratory operator, INEX Innovate has contributed an undisclosed sum to leading Hong Kong university The Chinese University of Hong Kong (CUHK), to collaborate and further research in the field of maternal fetal medicine.

INEX's Dr. Chia-Pin Chang with Prof. Richard Choy of The Chinese University of Hong Kong

The CUHK Department of Obstetrics & Gynaecology (O&G) is world-renowned for its many prominent contributions and high-impact publications in the scientific community, attributed to its pursuit towards advancing the frontiers of knowledge in O&G through clinical, scientific and translational research. This initiative will tap on the research expertise of CUHK to further advance LEXI, a novel fetal cell isolation technology developed by INEX Innovate.

LEXI is a Non Invasive Prenatal Diagnostic (NIPD) technology that isolates fetal cells from the unborn baby, contained in the pregnant mother's blood for the definitive analysis of in excess of 7000 potential rare fetal genetic conditions.

Currently, expectant mothers whose prenatal screening results show signs of fetal anomaly are often recommended to undergo prenatal diagnostic tests for a definitive diagnosis of fetal genetic abnormalities, as this allows for early medical treatment of these conditions. However, prevailing diagnostic procedures such as amniocentesis are invasive and carry a risk of pregnancy loss of up to approximately 5 per cent[1].

Developed by INEX's Chief Technology Officer, Dr. Chia-Pin Chang, The LEXI cell isolation and enrichment is a process that isolates, identifies, and extracts target cells such as fetal cells from blood samples. The LEXI microfluidic chip enables its microfabricated filter to successfully deplete most of non-target cells in a blood sample and effectively capture fetal cells. Clinicians will need to draw one tube of blood from an expectant mother to generate results of the health condition of the fetus.

Chief Executive of INEX Innovate, Kane Black remarked, "We're thrilled to support and further the research of LEXI withProfessor Richard Choy and his team at The Chinese University of Hong Kong (CUHK), the pioneer centre of scientific excellence that focus on translating research advances into clinical impact both locally and internationally.

Mr. Black further commented fetalcellsinmaternalbloodrepresentthe Holy Grail of prenatal diagnosis. The major challenge has been isolation of these cell from maternal blood owing to their rarity, we look forward to working on this potentially cutting edge medical breakthrough with CUHK."

"We are looking forward to developing a potentially important breakthrough technology in the field of maternal fetal medicine," said Prof. Choy, Department of Obstetrics & Gynaecology at The Chinese University of Hong Kong.

[1] Cynthia L. Anderson, MD, and Charles E. L. Brown, MD, MBA, "Fetal Chromosomal Abnormalities: Antenatal Screening and Diagnosis, American Family Physician, 2009 Jan 15;79(2):117-123.

About INEX Innovate:

INEX Innovate is one of Asia's fastest growing molecular diagnostics developers and medical laboratory operators.

Founded by veteran maternalfoetalmedicine specialists, INEX is uniquely positioned to identify and address clinically unmet needs within the fetal health and women'soncology landscape, with a broad commercial portfolio of validated tests and 48 key patents.

Through our wholly owned subsidiary iGene Laboratory Pte Ltd, INEX operates a state of the art Next Generation Sequencing Laboratory that provides diagnostic testing, clinical research (CRO) and COVID-19 testing services.

The company has been recognised globally with a number of accolades and awards including from Frost & Sullivan, the World Intellectual Property Organisation (WIPO), The Straits Times Singapore's Fastest Growing Companies and the Financial Times ranking of 500 of Asia Pacific's Fastest Growing Companies.

For more information please visit: http://www.inex.sg

About The Chinese University of Hong Kong (CUHK):

Founded in 1963, CUHK is a leading comprehensive research university with a global reputation. Located in the heart of Asia, CUHK has a vision and a mission to combine tradition with modernity, and to bring together China and the West. Under the University's unique collegiate system, the programmes and activities offered by its nine colleges complement the formal curricula by delivering whole-person education and pastoral care. The University has eight faculties: Arts, Business Administration, Education, Engineering, Law, Medicine, Science, and Social Science. Together with the Graduate School, the University offers over 300 undergraduate and postgraduate programmes. All faculties are actively engaged in research in a wide range of disciplines, with an array of research institutes and research centres specialising in interdisciplinary research of the highest quality.

The University currently has more than 1,400 granted patents in different jurisdictions worldwide. Some of these patents have been licensed to relevant industries that help bring these innovations to the market to benefit society. In academic year 2020-21, CUHK has received 226 granted patents and filed 386 patent applications for inventions developed in the areas of medical technology, biotechnology, information technology, telecommunications, and materials science.

See more here:
Molecular Diagnostics Developer INEX Innovate Announces Funding for New Research with The Chinese University of Hong Kong - PR Newswire APAC - PR...

Colorized scanning electron micrograph of a cell (pink) infected with a variant strain of SARS-CoV-2 virus particles (UK B.1.1.7; gold), isolated from a patient sample. Courtesy NIAID

UC San Diego researchers have found that a post-COVID lung disease shares origins with other scarring lung diseases, which may offer a path to effective therapies, according to a study released Wednesday.

Although most people recover relatively quickly from COVID-19, around one-third of survivors experience symptoms weeks and months after the initial infection. However, in the study published in Wednesdays online issue of eBioMedicine, UCSD scientists studied interstitial lung disease, a form of long COVID that consists of a group of chronic pulmonary disorders characterized by inflammation and scarring of the lung.

The researchers said little is currently known about ILD which can be fatal without a lung transplant in its most severe form. But they found insights into the causes and paths the disease may take.

Using an artificial intelligence approach, we found that lung fibrosis caused by COVID-19 resembles idiopathic pulmonary fibrosis, the most common and the deadliest form of ILD, said co-senior study author Dr. Pradipta Ghosh, professor in the departments of Medicine and Cellular and Molecular Medicine at UCSD School of Medicine. At a fundamental level, both conditions display similar gene expression patterns in the lungs and blood, and dysfunctional processes within alveolar type II cells.

Those AT2 cells play several roles in pulmonary function, including the production of lung surfactant that keeps lung cells from collapsing after exhalation and regeneration of lung cells after injury.

The findings are insightful because AT2 cells are known to contain an elegant quality control network that responds to stress, internal or external, Ghosh said. Failure of quality control leads to broader organ dysfunction and, in this case, fibrotic remodeling of the lung.

To conduct the study, Ghosh collaborated with co-author Debashis Sahoo, associate professor in the departments of Computer Science, Engineering and Pediatrics at UCSD for the AI assisted analysis among other aspects.

Ghosh and Sahoo said the approach would help them stay unbiased in navigating the unknowns of an emerging, post-pandemic disease. They analyzed more than 1,000 human lung datasets associated with various lung conditions, specifically looking for gene expression patterns, inflammation signaling and cellular changes. The disease with the closest match: IPF.

IPF affects around 100,000 people in the United States, with 30,000 to 40,000 new cases annually. The condition has a poor prognosis, with an estimated mean survival of 2 to 5 years from time of diagnosis.

City News Service contributed to this article.

Continued here:
UCSD Post-COVID Lung Disease Study May Unlock Path to Therapies - Times of San Diego